A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
- Author
- CHIT, K. N1 ; ELLARD, S. L2 ; WALSH, W8 ; SEYMOUR, L8 ; HOTTE, S. J3 ; CZAYKOWSKI, P4 ; MOORE, M5 ; RUETHER, J. D6 ; SCHELL, A. J7 ; TAYLOR, S7 ; HANSEN, C8 ; GAUTHIER, I8
[1] Department of Medical Oncology, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
[2] Department of Medical Oncology, Centre for the Southern Interior, BC Cancer Agency, Kelowna, Canada
[3] Department of Medical Oncology, Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Canada
[4] department of Medical Oncology, Cancer Care Manitoba, Winnipeg, Canada
[5] Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
[6] Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, Canada
[7] Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada
[8] IND Program, National Cancer Institute of Canada-Clinical Trials Group, Kingston, Canada - Source
Annals of oncology. 2008, Vol 19, Num 4, pp 746-751, 6 p ; ref : 22 ref
- ISSN
- 0923-7534
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- phase II clinical trial prostate cancer prostate-specific antigen sorafenib
- Keyword (fr)
- Anticancéreux Antigène spécifique prostate Cancer de la prostate Castration Essai clinique phase II Homme Marqueur tumoral Résistance Sorafénib Traitement Cancer Inhibiteur de la tyrosine kinase Inhibiteur enzyme Inhibiteur multikinase Pathologie de l'appareil génital mâle Pathologie de l'appareil urinaire Pathologie de la prostate Tumeur maligne
- Keyword (en)
- Antineoplastic agent Prostate specific antigen Prostate cancer Castration Phase II trial Human Tumoral marker Resistance Sorafenib Treatment Cancer Tyrosine kinase inhibitor Enzyme inhibitor Multikinase inhibitor Male genital diseases Urinary system disease Prostate disease Malignant tumor
- Keyword (es)
- Anticanceroso Antigeno específico prostata Cáncer de la próstata Castración Ensayo clínico fase II Hombre Marcador tumoral Resistencia Sorafenib Tratamiento Cáncer Inhibidor tyrosine kinase Inhibidor enzima inhibidor multicinasa Aparato genital macho patología Aparato urinario patología Prostata patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B14 Nephrology. Urinary tract diseases / 002B14D Tumors of the urinary system / 002B14D02 Urinary tract. Prostate gland
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20B Male genital diseases / 002B20B02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Nephrology. Urinary tract diseases Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20227367
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/annonc/mdm554 
https://dx.doi.org/10.1093/annonc/mdm554
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm554\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:95:\"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"746\";s:8:\"\u0000*\u0000epage\";s:3:\"751\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHIT\";s:10:\"\u0000*\u0000aufirst\";s:4:\"K. N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:12:\"ELLARD, S. L\";i:1;s:8:\"WALSH, W\";i:2;s:10:\"SEYMOUR, L\";i:3;s:11:\"HOTTE, S. J\";i:4;s:13:\"CZAYKOWSKI, P\";i:5;s:8:\"MOORE, M\";i:6;s:13:\"RUETHER, J. D\";i:7;s:12:\"SCHELL, A. J\";i:8;s:9:\"TAYLOR, S\";i:9;s:9:\"HANSEN, C\";i:10;s:11:\"GAUTHIER, I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:95:\"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm554\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:95:\"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"746\";s:8:\"\u0000*\u0000epage\";s:3:\"751\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHIT\";s:10:\"\u0000*\u0000aufirst\";s:4:\"K. N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:12:\"ELLARD, S. L\";i:1;s:8:\"WALSH, W\";i:2;s:10:\"SEYMOUR, L\";i:3;s:11:\"HOTTE, S. J\";i:4;s:13:\"CZAYKOWSKI, P\";i:5;s:8:\"MOORE, M\";i:6;s:13:\"RUETHER, J. D\";i:7;s:12:\"SCHELL, A. J\";i:8;s:9:\"TAYLOR, S\";i:9;s:9:\"HANSEN, C\";i:10;s:11:\"GAUTHIER, I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:95:\"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm554\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm554\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:95:\"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"746\";s:8:\"\u0000*\u0000epage\";s:3:\"751\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHIT\";s:10:\"\u0000*\u0000aufirst\";s:4:\"K. N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:12:\"ELLARD, S. L\";i:1;s:8:\"WALSH, W\";i:2;s:10:\"SEYMOUR, L\";i:3;s:11:\"HOTTE, S. J\";i:4;s:13:\"CZAYKOWSKI, P\";i:5;s:8:\"MOORE, M\";i:6;s:13:\"RUETHER, J. D\";i:7;s:12:\"SCHELL, A. J\";i:8;s:9:\"TAYLOR, S\";i:9;s:9:\"HANSEN, C\";i:10;s:11:\"GAUTHIER, I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:95:\"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm554\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:95:\"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"746\";s:8:\"\u0000*\u0000epage\";s:3:\"751\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHIT\";s:10:\"\u0000*\u0000aufirst\";s:4:\"K. N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:12:\"ELLARD, S. L\";i:1;s:8:\"WALSH, W\";i:2;s:10:\"SEYMOUR, L\";i:3;s:11:\"HOTTE, S. J\";i:4;s:13:\"CZAYKOWSKI, P\";i:5;s:8:\"MOORE, M\";i:6;s:13:\"RUETHER, J. D\";i:7;s:12:\"SCHELL, A. J\";i:8;s:9:\"TAYLOR, S\";i:9;s:9:\"HANSEN, C\";i:10;s:11:\"GAUTHIER, I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:95:\"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm554\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:95:\"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"746\";s:8:\"\u0000*\u0000epage\";s:3:\"751\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHIT\";s:10:\"\u0000*\u0000aufirst\";s:4:\"K. N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:12:\"ELLARD, S. L\";i:1;s:8:\"WALSH, W\";i:2;s:10:\"SEYMOUR, L\";i:3;s:11:\"HOTTE, S. J\";i:4;s:13:\"CZAYKOWSKI, P\";i:5;s:8:\"MOORE, M\";i:6;s:13:\"RUETHER, J. D\";i:7;s:12:\"SCHELL, A. J\";i:8;s:9:\"TAYLOR, S\";i:9;s:9:\"HANSEN, C\";i:10;s:11:\"GAUTHIER, I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:95:\"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
